NCT06023875 (NCCCNRHNSCC) is a Phase 2 clinical trial of Cadonilimab in Head and Neck Squamous Cell Carcinoma, sponsored by Xuekui Liu.

Who is sponsoring NCT06023875?

NCT06023875 is sponsored by Xuekui Liu.

What drugs are being tested in NCT06023875?

Interventions in NCT06023875: Cadonilimab, Docetaxel, Cisplatin.

What condition does NCT06023875 study?

NCT06023875 studies Head and Neck Squamous Cell Carcinoma, Locally Advanced Operable.

Is NCT06023875 still recruiting?

NCT06023875 is currently status unknown. Last updated 5 September 2023.

Last reviewed 2023-09-05 · How we verify

NCT06023875: NCCCNRHNSCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 5 September 2023

What this trial tests

Phase 2 trial testing Cadonilimab in Head and Neck Squamous Cell Carcinoma in 30 participants. Status unknown.

Timeline

19 July 2023

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Xuekui Liu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	19 July 2023
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	2 locations across China

Drugs / interventions tested

Cadonilimab — full drug profile →
Docetaxel (Docetaxel) — full drug profile →
Cisplatin (cisplatin) — full drug profile →

Conditions studied

Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Locally Advanced Operable — all drugs for Locally Advanced Operable →

Sponsor

Xuekui Liu

Who can join

Adults 18 to 70, any sex, with Head and Neck Squamous Cell Carcinoma or Locally Advanced Operable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single arm phase ll trial including 30 patients with T2N2-3M0、T3-4N0-3M0 (lll-V) head and neck squamous cell carcinoma (HNSCC) eligible forresection, who receive neo-adjvuant Cadonilimab combined with cisplatin and Nab.paclitaxel.This proposed study will evaluate the efficacy and safety of preoperativeadministration of Cadonilimab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) who are about to undergo surgery.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial.
Cao F, Li Y, Fang Q, Lin R, et al · · 2025 · cited 3× · PMID 40705040 · DOI 10.1158/1078-0432.ccr-25-1445
Evaluation of neoadjuvant immunotherapy regimens for head and neck squamous cell carcinoma: a systematic review and single-arm and network meta-analysis.
Ye Z, Fan W, Zeng B, Tan R, et al · · 2026 · PMID 41504501 · DOI 10.1097/js9.0000000000004689

Verify or expand the search:

Other trials of Cadonilimab

Trials testing the same drug.

NCT07446257 — THIO and Cadonilimab in Resectable Hepatocellular Carcinoma · EARLY_PHASE1 · not yet recruiting
NCT07243951 — Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therap · Phase 2 · not yet recruiting
NCT06913218 — A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically R · Phase 1 · not yet recruiting
NCT06940921 — SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases · Phase 1, PHASE2 · active not recruiting
NCT06789848 — Ligufalimab and Cadonilimab in Advanced Liver Cancers · Phase 2 · recruiting

Other recruiting trials for Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting

Other Xuekui Liu trials

Trials by the same sponsor.

NCT06107114 — Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcino · Phase 2 · unknown
NCT06130007 — A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06023875 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuekui Liu
Last refreshed: 5 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06023875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing